- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment PSP is a degenerative disease that, like Parkinson's disease, causes symptoms such ...

BARCELONA, Spain--(BUSINESS WIRE)--Ferrer, a B Corp-certified international pharmaceutical company, has announced the dosing of the first participant in the Phase II clinical trial, PROSPER. The study ...

Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AZP2006 (Ezeprogind®) for the treatment of ...

Progressive supranuclear palsy (PSP), a mysterious and deadly neurological disorder, usually goes undiagnosed until after a patient dies and an autopsy is performed. But now, UC San Francisco ...

Are efforts to target tau finally starting to pay off? Just a little, maybe? The Tau Global Conference, held in Washington, D.C., May 14 to 15, showcased recent progress in basic science, biomarkers, ...

For the past 20 years, Janet Edmunson has run support groups for patients with rare neurological diseases that have no known treatment or cure. What they want to know, Edmunson said, is "'When are ...

The inability to identify PSP has hampered the development of new treatments, according to co-senior author Adam Boxer, MD, PhD, endowed professor in memory and aging at the UCSF Department of ...